Amgen keeps Kineret
Executive Summary
Amgen will keep IL-1 inhibitor Kineret (anakinra) for treatment of rheumatoid arthritis under a proposed consent agreement between Amgen and Federal Trade Commission that would allow the company's proposed acquisition of Immunex to proceed. FTC's July 12 announcement of the agreement notes that Kineret has had sales in excess of $2.4 mil. since its launch in November. The agreement would require the company to divest one of Immunex' marketed products, the neutrophil regeneration factor Leukine (sargramostim) (1"The Pink Sheet" Dec. 24, 2001, p. 16)...